Loading...
•
Mar 31, 2020
Replimune Q4 2020 Earnings Report
Reported financial results for the fiscal fourth quarter and year ended March 31, 2020, and provided a business update.
Key Takeaways
Replimune Group, Inc. announced its financial results for the fiscal fourth quarter and year ended March 31, 2020. The company is focused on developing oncolytic immuno-gene therapies and plans to initiate clinical development of RP1 in anti-PD1 refractory patients with non-small cell lung cancer (NSCLC).
Continued progress developing pipeline of oncolytic immuno-gene therapies.
Released additional data with RP1 in lead indications of cutaneous squamous cell carcinoma (CSCC) and anti-PD1 refractory cutaneous melanoma.
Announced plans to initiate clinical development of RP1 in anti-PD1 refractory patients with non-small cell lung cancer (NSCLC).
Established clinical proof of principle with RP1 in immune-responsive tumor types.
Forward Guidance
Replimune believes that its existing cash and cash equivalents and short-term investments along with its debt commitments will enable it to fund its operating expenses and capital expenditure requirements through 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...